Notes for P&L
All amounts in SEKm unless otherwise stated
Note 19 Non-current finanical assets
| Parent Company | ||||||
|---|---|---|---|---|---|---|
| Receivables from Group companies | 2022-12-31 | 2021-12-31 | ||||
| Opening balance | 6,589 | 1,709 | ||||
| Increase during the year | 2,282 | 5,090 | ||||
| Decrease during the year | -1,272 | -210 | ||||
| Carrying amount at year-end | 7,599 | 6,589 | ||||
| Specification of interests in Group companies | Country | Number of shares | Quotient value | Holding % | Carrying amount 2022-12-31 | Carrying amount 2021-12-31 |
| AddLife Development AB | Sweden | 1,000 | 100 | 100% | 389 | 389 |
| Interests in Group companies | Parent Company | |||||
| Accumulated cost | 2022 | 2021 | ||||
| Opening balance | 389 | 389 | ||||
| Acquisitions for the year | - | 4,479 | ||||
| Disposals for the year¹ | - | -4,479 | ||||
| Closing balance | 389 | 389 | ||||
| ¹ Internal sale year 2021 of Primacy Healthcare 21 Limited and AddVision Holding GmbH. | ||||||
| Indirect ownership | |||||||
|---|---|---|---|---|---|---|---|
| Indirect ownership | Ownership | Indirect ownership | Ownership | Indirect ownership | Ownership | ||
| Biomedica Medizinprodukte GmbH | 100% | V-tech AB | 100% | BioNordika (Denmark) A/S | 100% | ||
| Euromed Swiss AG | 100% | Väinö Korpinen Oy | 100% | BioNordika Bergman AS | 100% | ||
| Biomedis d.o.o. | 100% | Triolab Oy | 100% | BioNordika (Sweden) AB | 100% | ||
| Biomedica MP d.o.o. | 100% | Triolab AB | 100% | BioNordika (Finland) Oy | 100% | ||
| Biomedica Dijagnostika doo | 100% | Triolab (Baltics) Oy | 100% | Dach Medical Group Holding AG | 100% | ||
| Biomedica d.o.o. | 100% | LabRobot Products AB | 100% | Dach Austria Medical Group GmbH | 100% | ||
| Biomedica Bulgaria ood | 100% | BergmanLabora AB | 100% | Dach Switzerland Medical Group GmbH | 100% | ||
| Biomedica Medizinprodukte Romania SRL | 100% | Biolin Scientific AB | 100% | D-A-CH Germany Medical Group GmbH | 100% | ||
| Biomedica Hungaria Kft. | 100% | Biolin Scientific China | 100% | Hepro AS | 100% | ||
| Biomedica CS s.r.o. | 100% | Biolin Scientific Oy | 100% | Ropox A/S | 100% | ||
| Biomedica Poland Sp. Zo.o. | 100% | Biolin Scientific LTD | 100% | Zafe Care Systems AB | 100% | ||
| Biomedica Dijagnostika d.o.o.el | 100% | Holm & Halby A/S | 100% | Biomedica Italia s.r.l | 100% | ||
| Biomedica Slovakita s.r.o. | 80% | Ocellus Vision Holding AG | 100% | Primacy Healthcare 21 Limited | 100% | ||
| Mediplast AB | 100% | Medilas AG | 100% | Aquilant Northern Ireland Limited | 100% | ||
| Mediplast AS | 100% | Polytech Ophthalmologie AG | 100% | Aquilant Limited | 100% | ||
| Mediplast Sataside Oy | 100% | Polytech Domilens GmbH | 100% | Medscope Limited | 100% | ||
| Mediplast S.r.l | 100% | M.E.D. Medical Products GmbH, Germany | 100% | Aquilant Endoscopy Limited | 100% | ||
| Mediplast Benelux B.V. | 100% | Vision Ophthalmology Holding One GmbH | 100% | Healtcare Acquisitions Limited | 100% | ||
| Mediplast GmbH | 100% | Vision Ophthalmology Group GmbH | 100% | Tools For Living (Ireland) Limited | 100% | ||
| Mediplast A/S | 100% | Spectrum Ophthalmology Ltd | 100% | Lyncare Systems Limited | 100% | ||
| Mediplast Iberia SL | 100% | POLYMED Polska Sp.z.oo | 75% | Healthcare 21 (UK) Limited | 100% | ||
| Hospidana A/S | 100% | Visop Nordic AB | 100% | Healthcare 21 (DE) GmbH | 100% | ||
| Fenno Medical Oy | 100% | SSCP Blink BidCo Ltd | 100% | Healthcare 21 (AT) GmbH | 100% | ||
| TechniPro PulmoMed Pty Ltd | 100% | Vision Pharmaceuticals Ltd | 100% | Primacy Healthcare 21 International Limited | 100% | ||
| Fischer Medical AS | 100% | MALA Holding B.V. | 100% | Asset Tracker Solutions Limited | 100% | ||
| Camanio AB | 100% | Bio-Connect B.V. | 100% | Aquilant Scientific (ROI) Limited | 100% | ||
| Bestic AB | 100% | Bio-Connect Diagnostics B.V. | 100% | Aquilant Medical (ROI) Limited | 100% | ||
| Lab-Vent Controls A/S | 100% | Bio-Connect Services B.V. | 100% | Xograph Healthcare Limited | 100% | ||
| Immuno Diagnostics Oy | 100% | European Warehousing Services B.V. | 100% | Xograph Healthcare (Ireland) Limited | 100% | ||
| Bergman Diagnostika AS | 100% | Pharma-Connect B.V. | 100% | Glanadh Medical Holdings Limited | 100% | ||
| EuroClone S.p.A. | 100% | N.V. Forlab SA | 100% | O'Flynn Medical Limited | 100% | ||
| Funksjonsutstyr AS | 76% | MBA Incorporado S.L. | 100% | O'Flynn Innovation Limited | 100% | ||
| Svan Care AB | 100% | MBA Italia S.R.L | 100% | JK Lab AB | 100% | ||
| Esthe-Tech AB | 100% | MBA Portugal S.A. | 100% | BioCat GmbH | 100% | ||
Accounting principle
Interests in Group companies are recognised in the Parent Company using the cost method, which means that transaction costs are included in the carrying amount for holdings in subsidiaries. Any changes in liabilities for contingent consideration are added to or reduce the (acquisition) cost. In the Group, transaction costs are expensed and changes in liabilities for contingent considerations are entered as income or expense. Shareholder contributions provided by the Parent Company are recognized in shares, when impairment is not required.
To the top